

Adjuvant Treatment

| GUIDELINE | DOCUMENT | ORGANISATION/ COUNTRY | YEAR PUBLISHED |
|--|---|--|-------------------|
| Bisphosphonates | Benefits of Adjuvant Bisphosphonates in Postmenopausal women | UK National Breast Clinical Reference Group & UK Breast Cancer Group, UK | 2016 |
| <p>Comments:</p> <p>The UK Breast Cancer Group have produced a very helpful 2 page summary of the benefits of bisphosphonates as adjuvant treatment in breast cancer patients.</p> | | | |
| Bisphosphonates | Clinical advice to Cancer Alliances for the provision of Breast Cancer Services | Breast Cancer Clinical Expert Group, UK | 2017 |
| <p>Comments:</p> <p>The 2017 publication from the Breast Cancer Clinical Expert Group is not a guidance document per se but instead a list of best practice recommendations to commissioners and acute trusts for a modern breast service. It includes a recommendation that bisphosphonates should be offered to postmenopausal women "to reduce the risk of bone recurrence and fractures, and improve breast cancer survival"</p> | | | |
| Endocrine therapy | Endocrine treatment for breast cancer | Association of Breast Surgery, UK | 2021 |
| <p>Comments:</p> <p>ABS have produced an up to date guideline on endocrine therapy for early breast cancer patients</p> | | | |
| Radiotherapy | Postoperative radiotherapy for breast cancer: UK consensus statement | Royal College of Radiologists (RCR), UK | 2016 |
| <p>Comments:</p> <p>ASCO have produced recommendations on the requirements for postmastectomy chest wall irradiation in patients with T1-2 tumours and 1-3 positive axillary nodes or patients with a positive sentinel node who do not undergo further axillary surgery.</p> <p>Recommendations for axillary radiotherapy in patients who have received neoadjuvant systemic treatment and for irradiation of internal mammary nodes and the supraclavicular fossa are also presented.</p> <p>ABS supports this document and its use in the context of a multidisciplinary meeting.</p> | | | |

Guidance Platform

Adjuvant Treatment

| GUIDELINE | DOCUMENT | ORGANISATION/ COUNTRY | YEAR PUBLISHED |
|----------------------|--|--|-------------------|
| Treatment guidelines | Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10) | National Institute for Health & Care Excellence (NICE), UK | 2013 |

Comments:

NICE have evaluated the relative benefits of Oncotype DX, Mammaprint, IHC4 and Mammostrat in guiding the use of adjuvant chemotherapy for patients with hormone receptor positive, lymph node negative, HER2 negative breast cancer.

| | |
|----------------|--------------|
| Date | January 2021 |
| Version | 2 |

The guideline title in the document column includes a hyperlink to the relevant guideline. Please view the document on the ABS website to follow these links.